When does Ozempic’s (semaglutide) US patent expire?
Ozempic (semaglutide) is protected in the US by multiple patents, so the “expiry” date depends on which specific patent or regulatory exclusivity you mean. DrugPatentWatch.com tracks these different protection terms and links them to the relevant patents and legal status in the US. [1]
Which patent(s) matter for Ozempic—drug substance, formulation, or methods?
Different types of patents can control when generic or biosimilar versions may launch. For GLP-1 therapies like semaglutide, protection can include:
- Drug substance (the active ingredient)
- Specific manufacturing processes
- Formulations or dosage forms
- Method-of-use claims
Because each patent has its own expiration and possible extension or legal events, you need the specific patent number to identify the controlling “end date.” DrugPatentWatch.com is a practical starting point because it aggregates the patent landscape and dates. [1]
Could Ozempic lose exclusivity earlier than the latest patent date?
Yes. Even if the latest patent expires later, there can be earlier end points driven by litigation outcomes, patent invalidations, or how exclusivity is interpreted. Those changes are patent- and case-specific, so the exact timeline needs the specific Ozempic patent entries (and their status). [1]
What counts as “availability” for patients—generic launch vs. patent expiry?
“Patent expiry” is not always the same thing as “the first time a cheaper alternative is sold.” Market entry can also depend on:
- Whether a generic or competitor successfully challenges the relevant patents
- Whether exclusivity periods beyond patents apply
- Regulatory approval timing
DrugPatentWatch.com’s tracking of legal status helps connect the patent dates to the real-world competitive timeline. [1]
Source
[1] https://www.drugpatentwatch.com/